Resumo
Definição
História e exame físico
Principais fatores diagnósticos
- presença de fatores de risco
- baixa estatura
- velocidade de crescimento deficitária
- baixo para a altura-alvo
- ausência do estirão de crescimento puberal e/ou puberdade tardia
- sintomas de tumor no sistema nervoso central (suprasselar)
- sintomas de outras disfunções hormonais hipofisárias
- aparência facial característica
Outros fatores diagnósticos
- parto instrumental
- comprometimento visual
- características dismórficas associadas
- deficits neurológicos focais
- hiperfagia/obesidade
- temperatura desregulada/distúrbio do sono
- problemas comportamentais
Fatores de risco
- história familiar de DGH
- outras deficiências hormonais hipofisárias
- tumores/cistos do sistema nervoso central (SNC)
- radioterapia
- anomalias na linha média
- doenças infiltrativas do SNC
- complicações perinatais
- trauma do SNC
- distúrbio de sobrecarga de ferro preexistente
- abuso infantil
- infecções do SNC
Investigações diagnósticas
Primeiras investigações a serem solicitadas
- radiografia de punho
- testes da função tireoidiana
- fator de crescimento semelhante à insulina-1 (IGF-1) e proteína 3 de ligação ao IGF (IGFBP3)
- testes da função hipofisária basais
- perfil básico de hematologia e bioquímica
Investigações a serem consideradas
- teste de provocação de hormônio do crescimento (GH)
- ressonância nuclear magnética (RNM) cranioencefálica
- tomografia computadorizada (TC) cranioencefálica/radiografia do crânio
- avaliação hormonal hipofisária completa
- encaminhamento a especialista
- estudos genéticos
- hormônio do crescimento (GH) aleatório
Algoritmo de tratamento
deficiência de hormônio do crescimento (GH) confirmada
Colaboradores
Autores
Hoong-Wei Gan, BMedSci (Hons), BMBS, MSc, PhD, MRCPCH
Consultant Paediatric Endocrinologist
Great Ormond Street Hospital for Children NHS Foundation Trust
London
UK
Declarações
HWG is currently taking part in sponsored research (ongoing) for Pfizer Registry of Outcomes In GH Research (PROGRES). HWG has been previously invited to write a review article for The Lancet Diabetes & Endocrinology titled National UK guidelines for the management of paediatric craniopharyngioma for which he received financial compensation. HWG has been invited to give a lecture at the PE Connect Symposium, sponsored by an educational grant from Ipsen Ltd. He is an author of references cited in this topic.
Harshini Katugampola, BSc, MBBS, MSc, PhD, MRCPCH
Consultant Paediatric Endocrinologist
Great Ormond Street Hospital for Children NHS Foundation Trust
London
UK
Declarações
HK is an author of references cited in this topic.
Agradecimentos
Dr Hoong-Wei Gan and Dr Harshini Katugampola would like to gratefully acknowledge Dr Ameeta Mehta, Professor Mehul T. Dattani, and Dr Kyriaki S. Alatzoglou, previous contributors to this topic.
Declarações
AM is an author of references cited in this topic. MTD received lecture fees from Novo Nordisk, Pfizer, and Ipsen; consultancy fees from Novo Nordisk, Pfizer, Ipsen, and Sandoz; and was a member of a Novo Nordisk advisory board. Novo Nordisk, Pfizer, Ferring, Ipsen, Lilly, Merck, and Serono have made financial contributions to MTD's departmental teaching programme. MTD declared that none of these activities are related to this topic. MTD is an author of references cited in this topic. KSA is an author of references cited in this topic.
Revisores
Martin Savage, MA, MD, FRCP, MRCPCH
Professor of Paediatric Endocrinology (Emeritus)
Department of Endocrinology
William Harvey Research Institute
St Bartholomew's and the Royal London School of Medicine and Dentistry
John Vane Science Centre
London
UK
Declarações
MS has received honoraria and consultancy payments from Ipsen, Pfizer, Novo Nordisk, and Merck Serono.
Paul Saenger, MD, MACE
Professor of Pediatrics
Department of Pediatrics (Endocrinology)
Montefiore Medical Center
Albert Einstein College of Medicine
New York
NY
Declarações
PS declares that he has no competing interests.
Referências
Principais artigos
Hage C, Gan HW, Ibba A, et al. Advances in differential diagnosis and management of growth hormone deficiency in children. Nat Rev Endocrinol. 2021 Oct;17(10):608-24. Resumo
GH Research Society. Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society. J Clin Endocrinol Metab. 2000 Nov;85(11):3990-3.Texto completo Resumo
Grimberg A, DiVall SA, Polychronakos C, et al. Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency. Horm Res Paediatr. 2016;86(6):361-97.Texto completo Resumo
Yuen KCJ, Biller BMK, Radovick S, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of growth hormone deficiency in adults and patients transitioning from pediatric to adult care. Endocr Pract. 2019 Nov;25(11):1191-232.Texto completo Resumo
Artigos de referência
Uma lista completa das fontes referenciadas neste tópico está disponível para os usuários com acesso total ao BMJ Best Practice.
Diagnósticos diferenciais
- Baixa estatura idiopática
- Atraso constitucional no crescimento
- Baixa estatura familiar
Mais Diagnósticos diferenciaisDiretrizes
- Guidelines for management of growth hormone deficiency in adults and patients transitioning from pediatric to adult care
- Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency
Mais DiretrizesFolhetos informativos para os pacientes
Diabetes do tipo 2: devo tomar insulina?
Diabetes: o que posso fazer para me manter saudável?
Mais Folhetos informativos para os pacientes
Conectar-se ou assinar para acessar todo o BMJ Best Practice
O uso deste conteúdo está sujeito ao nosso aviso legal